📣 VC round data is live. Check it out!
- Public Comps
- SenzaGen
SenzaGen Valuation Multiples
Discover revenue and EBITDA valuation multiples for SenzaGen and similar public comparables like CurveBeam AI, EBM Technologies, Diagnos, Biosynex and more.
SenzaGen Overview
About SenzaGen
SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.
Founded
2010
HQ

Employees
34
Website
Financials (FY)
EV
$18M
Valuation Multiples
Start free trialSenzaGen Financials
SenzaGen reported last fiscal year revenue of $6M and negative EBITDA of ($901K).
In the same fiscal year, SenzaGen generated $4M in gross profit, ($901K) in EBITDA losses, and had net loss of ($1M).
SenzaGen P&L
In the most recent fiscal year, SenzaGen reported revenue of $6M and EBITDA of ($901K).
SenzaGen is unprofitable as of last fiscal year, with gross margin of 65%, EBITDA margin of (14%), and net margin of (20%).
Financial data powered by Morningstar, Inc.
SenzaGen Stock Performance
SenzaGen has current market cap of $19M, and enterprise value of $18M.
Market Cap Evolution
SenzaGen's stock price is $0.58.
SenzaGen share price increased by 0.3% in the last 30 days, and by 3.8% in the last year.
SenzaGen has an EPS (earnings per share) of $-0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18M | $19M | 0.5% | 0.3% | -5.8% | 3.8% | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSenzaGen Valuation Multiples
SenzaGen trades at 2.9x EV/Revenue multiple, and (20.1x) EV/EBITDA.
SenzaGen Financial Valuation Multiples
As of May 8, 2026, SenzaGen has market cap of $19M and EV of $18M.
SenzaGen has a P/E ratio of (15.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SenzaGen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


SenzaGen Margins & Growth Rates
In the most recent fiscal year, SenzaGen reported gross margin of 65%, EBITDA margin of (14%), and net margin of (20%).
SenzaGen Margins
SenzaGen Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
SenzaGen Operational KPIs
SenzaGen's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
SenzaGen Competitors
SenzaGen competitors include CurveBeam AI, EBM Technologies, Diagnos, Biosynex, NanoRepro, Predilife, Biomaxima, Immunovia, Synthetic MR and ContextVision.
Most SenzaGen public comparables operate across Medical Imaging & Diagnostics and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.3x | 3.6x | (4.0x) | (4.0x) | |||
| 2.3x | — | 20.0x | — | |||
| 215.3x | — | (6.3x) | — | |||
| 0.7x | — | (3465.7x) | — | |||
| 2.6x | 0.7x | (3.5x) | (9.6x) | |||
| 26.1x | — | (4.1x) | — | |||
| 1.2x | — | 13.7x | — | |||
| 66.1x | 23.6x | (0.6x) | (0.5x) | |||
This data is available for Pro users. Sign up to see all SenzaGen competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SenzaGen
| When was SenzaGen founded? | SenzaGen was founded in 2010. |
| Where is SenzaGen headquartered? | SenzaGen is headquartered in Sweden. |
| How many employees does SenzaGen have? | As of today, SenzaGen has over 34 employees. |
| Is SenzaGen publicly listed? | Yes, SenzaGen is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of SenzaGen? | SenzaGen trades under SENZA ticker. |
| When did SenzaGen go public? | SenzaGen went public in 2017. |
| Who are competitors of SenzaGen? | SenzaGen main competitors include CurveBeam AI, EBM Technologies, Diagnos, Biosynex, NanoRepro, Predilife, Biomaxima, Immunovia, Synthetic MR, ContextVision. |
| What is the current market cap of SenzaGen? | SenzaGen's current market cap is $19M. |
| What is the current revenue of SenzaGen? | SenzaGen's last fiscal year revenue is $6M. |
| What is the current EV/Revenue multiple of SenzaGen? | Current revenue multiple of SenzaGen is 2.9x. |
| Is SenzaGen profitable? | No, SenzaGen is not profitable. |
| How many companies SenzaGen has acquired to date? | SenzaGen hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies SenzaGen has invested to date? | SenzaGen hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to SenzaGen
Lists including SenzaGen
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.